OTC Markets OTCQX - Delayed Quote • USD Orexo AB (publ) (ORXOY) Follow Compare 1.9750 0.0000 (0.00%) At close: January 8 at 3:00:00 PM EST Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for ORXOY 1D 5D 4.77% 1M 66.67% 3M 30.79% 6M -6.84% YTD 4.77% 1Y 30.79% 5Y -70.08% All -57.07% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: ORXOY View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis Abera and Orexo partner for vaccine powder formulations Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology Orexo initiates new study of OX640 in participants with allergic rhinitis Orexo AB (ORXOY) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ... Orexo Interim Report Q3 2024 Orexo´s Nomination Committee for the Annual General Meeting 2025 Orexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024 FDA issues CRL to Orexo’s NDA for opioid overdose medication Orexo Q2 2024 Interim Report Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose